Clinical significance of neutrophil extracellular traps biomarkers in thrombosis

Xu, Xiangbo; Wu, Yuting; Xu, Shixue; Yin, Yue; Ageno, Walter; De Stefano, Valerio; Zhao, Qingchun; Qi, Xingshun

doi:10.1186/s12959-022-00421-y

Thrombosis Journal

Table 4 Studies evaluating NETs biomarkers in cancer-associated thromboembolism

From: Clinical significance of neutrophil extracellular traps biomarkers in thrombosis

First author/year	Study design	Included patients	Groups (No. patients)	Samples processing	NETs biomarkers	Analytical methods for NETs biomarkers	Detailed values
Thålin et al (2016) [88]	Case–control	Patients with IS	Cancers (n = 8) vs. No cancers (n = 23)	Plasma, 2000 × g, 20 min	H3Cit	ELISA	0.22 vs. 0.07 OD
					MPO	ELISA	74.1 vs. 37.8 ng/mL
					DNA	PicoGreen fluorimetry	504.0 vs. 407.9 ng/mL
Mauracher et al (2018) [94]	Cohort	Adult patients with newly diagnosed malignancy or progression of disease after remission	VTE (n = 89) vs. No VTE (n = 857)	Plasma, 3000 × g, 10 min	H3Cit	ELISA	52.4 vs. 24.1 ng/mL
					Nucleosomes	ELISA	1.3 vs. 1.2 MoM
					DNA	PicoGreen fluorimetry	384.5 vs. 355.8 ng/mL
Bang et al (2019) [95]	Case–control	Patients with active cancer	Cancer-stroke (n = 38) vs. Stroke-control (n = 40) vs. Cancer-control (n = 27) vs. HC (n = 33)	Plasma, 2000 × g, 15 min	Nucleosomes	ELISA	0.379 vs. 0.189 vs. 0.251 vs. 0.194 OD
Bang et al (2019) [95]	Case–control	Patients with active cancer		Plasma, 2000 × g, 15 min	DNA	PicoGreen fluorimetry	40.35 vs. 34.38 vs. 34.52 vs. 30.48 mg/mL
Grilz et al (2019) [96]	Cohort	Adult patients with newly diagnosed malignancy or a progression of disease after complete or partial remission	ATE (n = 22) vs. No ATE (n = 935)	Plasma, 3000 × g, 10 min	H3Cit	ELISA	NA
					Nucleosomes	ELISA	NA
					DNA	PicoGreen fluorimetry	NA
Guy et al (2019) [98]	Case–control	Patients with MPN	Thrombosis (n = 16) vs. No thrombosis (n = 15)	Plasma, 2400 × g, 15 min	DNA	PicoGreen fluorimetry	NA
Guy et al (2019) [98]	Case–control	Patients with MPN	Thrombosis (n = 16) vs. No thrombosis (n = 15)	Plasma, 2400 × g, 15 min	MPO-DNA	ELISA	NA
Seo et al (2019) [97]	Case–control	Patients with HCC	PVT (n = 77) vs. No PVT (n = 100)	Plasma, 1550 × g, 15 min	DNA-histone	ELISA	159 vs. 83 AU
					NE	ELISA	NA
					DNA	PicoGreen fluorimetry	142.1 vs. 127.0 ng/mL

Abbreviations: ATE Arterial thromboembolism, AU Absorbance unit, ELISA Enzyme-linked immunosorbent assay, H3Cit Citrullinated histone H3, HC Healthy control, HCC Hepatocellular carcinoma, IS Ischemic stroke, Min Minute, MPN Myeloproliferative neoplasms, MPO Myeloperoxidase, NA Not available, NE Neutrophil elastase, NETs Neutrophil extracellular traps, OD Optical density, PVT Portal vein thrombosis, VTE Venous thromboembolism

Back to article page

ISSN: 1477-9560

Contact us

Submission enquiries: journalsubmissions@springernature.com